{"schema_version":"1","generated_at":"2026-11-03T22:10:43.768Z","data_as_of":null,"url":"https://www.findmykol.com/kol/suleiman-massarweh","json_url":"https://www.findmykol.com/kol/suleiman-massarweh/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"suleiman-massarweh","name":"Suleiman Massarweh","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Stanford Medicine","institution_url":"https://www.findmykol.com/institution/stanford-university-school-of-medicine","city":"Stanford","state":"CA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1972619708","openalex":"A5113787895"},"summary":"Suleiman Massarweh is an Oncology physician affiliated with Stanford Medicine. OpenAlex indexes 65 publications with 4,549 citations (h-index 24); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":65,"cited_by_count":4549,"h_index":24,"latest_activity_year":2025,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT00525161","title":"Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer","phase":"PHASE2","status":"TERMINATED","role":"Overall official","sponsor":"Suleiman Massarweh","source_url":"https://clinicaltrials.gov/study/NCT00525161","trial_url":"https://www.findmykol.com/trial/NCT00525161"}],"source":"trials"},"payments":{"company_count":1,"program_years":{"first":2021,"last":null},"rows_total":1,"shown":1,"withheld":0,"rows":[{"payer":"Gilead Sciences, Inc.","program_year":2021,"amount_usd":11.92,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1972619708"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1972619708","source":"payments"},"prescribing":{"data_year":2020,"areas_total":1,"areas_shown":1,"areas":[{"area":"Cancer & immunology","share_pct":100,"classes_total":1,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":100,"drugs":[{"name":"Anastrozole","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2019,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Etirinotecan Pegol ( NKTR ‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer","year":2025,"journal":"Cancer Reports","source_url":"https://doi.org/10.1002/cnr2.70330","status":"verified"},{"title":"Malignant phyllodes tumor metastatic to pancreas","year":2020,"journal":"The Breast Journal","source_url":"https://doi.org/10.1111/tbj.13987","status":"verified"},{"title":"Molecular Characterization and Mortality From Breast Cancer in Men","year":2018,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2017.76.8861","status":"verified"},{"title":"Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers","year":2018,"journal":"Cell Death and Disease","source_url":"https://doi.org/10.1038/s41419-017-0072-x","status":"verified"},{"title":"Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance","year":2016,"journal":"Molecular Cancer Research","source_url":"https://doi.org/10.1158/1541-7786.mcr-15-0423","status":"verified"}],"source":"works"},"contact":{"address_1":"300 PASTEUR DR","city":"Stanford","state":"CA","zip":"943052200","phone":"650-723-4000","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1972619708","source":"identity"},"similar":[{"name":"Jeffrey Teuteberg","slug":"jeffrey-teuteberg","institution":"Stanford Medicine","specialty":"Advanced Heart Failure and Transplant Cardiology","url":"https://www.findmykol.com/kol/jeffrey-teuteberg","json_url":"https://www.findmykol.com/kol/jeffrey-teuteberg/profile.json"},{"name":"Charles Debattista","slug":"charles-debattista","institution":"Stanford Medicine","specialty":"Psychiatry","url":"https://www.findmykol.com/kol/charles-debattista","json_url":"https://www.findmykol.com/kol/charles-debattista/profile.json"},{"name":"Jong Yoon","slug":"jong-yoon","institution":"Stanford Medicine","specialty":"Psychiatry","url":"https://www.findmykol.com/kol/jong-yoon","json_url":"https://www.findmykol.com/kol/jong-yoon/profile.json"},{"name":"Kimberly Dequattro","slug":"kimberly-dequattro","institution":"Stanford Medicine","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/kimberly-dequattro","json_url":"https://www.findmykol.com/kol/kimberly-dequattro/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2015-03-31","collected_at":"2026-11-03T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2020}},"methodology_url":"https://www.findmykol.com/about#methodology"}